Sarepta Therapeutics (NASDAQ:SRPT) Sets New 52-Week Low at $77.01


Share on StockTwits

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s share price hit a new 52-week low during trading on Tuesday . The company traded as low as $77.01 and last traded at $83.00, with a volume of 18680 shares changing hands. The stock had previously closed at $83.11.

A number of brokerages have commented on SRPT. Mizuho reduced their price objective on Sarepta Therapeutics from $204.00 to $158.00 and set a “buy” rating for the company in a research note on Friday, January 8th. Cantor Fitzgerald cut their target price on Sarepta Therapeutics from $217.00 to $128.00 and set an “overweight” rating on the stock in a research report on Friday, January 8th. UBS Group cut Sarepta Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, January 11th. Royal Bank of Canada cut their target price on Sarepta Therapeutics from $200.00 to $143.00 and set an “outperform” rating on the stock in a research report on Friday, January 8th. Finally, SVB Leerink cut their target price on Sarepta Therapeutics from $197.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, January 8th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $160.38.

The stock has a market capitalization of $6.52 billion, a P/E ratio of -10.37 and a beta of 2.01. The company has a 50 day simple moving average of $97.14 and a 200-day simple moving average of $134.68. The company has a debt-to-equity ratio of 0.79, a current ratio of 6.14 and a quick ratio of 5.56.

In other news, insider Joseph Bratica sold 1,125 shares of Sarepta Therapeutics stock in a transaction dated Tuesday, December 8th. The shares were sold at an average price of $160.00, for a total value of $180,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 5.90% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of SRPT. Pathstone Family Office LLC raised its position in shares of Sarepta Therapeutics by 270.9% in the third quarter. Pathstone Family Office LLC now owns 204 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 149 shares during the period. Baillie Gifford & Co. bought a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $30,000. HM Payson & Co. bought a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $76,000. Exchange Traded Concepts LLC bought a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $90,000. Finally, Pacer Advisors Inc. purchased a new stake in shares of Sarepta Therapeutics in the third quarter worth about $93,000. 89.69% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

Further Reading: How to Invest in Marijuana Stocks

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.